# US 2026/0232793 A1 · Methods of Selecting T Cell Line and Donor Thereof for Adoptive Cellular Therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0232793 A1
- Document ID: US20260232793A1
- Status: Published application
- Kind: A1
- Application number: 19/429,070
- Filed: 2025-12-22
- Published: 2026-08-13
- Earliest claimed: 2014-11-05
- Assignees: Memorial Sloan Kettering Cancer Center
- Applicants: Memorial Sloan Kettering Cancer Center
- Inventors: Richard J. O'Reilly; Ekaterina Doubrovina; Guenther Koehne; Aisha N. Hasan; Susan E. Prockop
- Web page: https://patentgrep.com/patent/US20260232793A1

## CPC

- A61K 39/25: Varicella-zoster virus
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/46: Viral antigens
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/04: for throat disorders
- A61P 13/08: of the prostate
- A61P 13/10: of the bladder
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/16: Otologicals
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 33/00: Antiparasitic agents
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/04: Immunostimulants
- C12Q 1/6881: for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
- G01N 33/505: {involving T-cells}
- G01N 33/575: for cancer
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- G16B 35/00: ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
- G16B 35/20: Screening of libraries
- G16B 45/00: ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks
- G16C 20/60: In silico combinatorial chemistry
- A61K 2039/572: {cytotoxic response}
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/172: Haplotypes
- G01N 2333/03: Herpetoviridae, e.g. pseudorabies virus
- G01N 2333/045: Cytomegalovirus
- G01N 2333/05: Epstein-Barr virus
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16C: COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE

## Abstract

Disclosed herein are methods of selecting an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer. Also disclosed are methods of selecting a donor from whom to derive an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer.

## Claims

### Claim 1

A method of selecting an allogeneic T cell line for therapeutic administration to a human patient having or suspected of having a pathogen or cancer, comprising:
selecting a T cell line allogeneic to the patient that recognizes at least one epitope of an antigen of the pathogen or the cancer, using a representation that (i) identifies a plurality of HLA alleles and optionally HLA allele combinations, and (ii) discloses indications of relative activities of T cell lines, each recognizing at least one epitope of an antigen of the pathogen or cancer, and restricted to different ones of the HLA alleles or HLA allele combinations in the plurality; wherein in the representation each identified HLA allele or HLA allele combination is associated with the respective indication of relative activity of the T cell line restricted to the HLA allele or HLA allele combination, the relative activities being relative measures of known activity against the pathogen or against the cancer exhibited by the T cell lines; wherein
(A) the T cell line selected has in common with the patient or diseased cells in the patient the HLA allele or HLA allele combination identified by the representation to which the recognition of the T cell line is restricted; and
(B) the HLA allele or HLA allele combination, to which the T cell line selected is restricted, is associated in the representation with an indication of the highest relative activity among the HLA alleles and HLA allele combinations in the representation that are known to be in common with the patient or the diseased cells in the patient and are not otherwise disqualified.

### Claim 2 (depends on 1)

The method of claim 1, which further comprises prior to the selecting step, a step of generating the representation.

### Claim 3 (depends on 2)

The method of claim 2, which further comprises prior to the generating step, a step of measuring the relative activities.

### Claim at position 4

-5. (canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein the representation is a list of the plurality of HLA alleles and optionally HLA allele combinations ranked by the relative activities.

### Claim 7 (depends on 1)

The method of claim 1, wherein the representation is a database listing the plurality of HLA alleles and optionally HLA allele combinations, each associated with a score indicative of relative activity.

### Claim at position 7

-9. (canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein the relative activities are in vivo clinical efficacies of the T cell lines in treatment of patients having the pathogen or the cancer.

### Claim at position 9

-12. (canceled)

### Claim 13 (depends on 1)

The method of claim 1, wherein the patient has or is suspected of having a pathogen, wherein the T cell lines recognize at least one epitope of an antigen of the pathogen, and wherein the relative activities are relative measures of known activity against the pathogen.

### Claim 14

(canceled)

### Claim 15 (depends on 13)

The method of claim 13, wherein the pathogen is a virus.

### Claim 16 (depends on 15)

The method of claim 15, wherein the virus is CMV.

### Claim 17 (depends on 16)

The method of claim 16, wherein the patient has or is suspected of having a CMV infection subsequent to the patient having undergone a hematopoietic stem cell transplant (hereinafter “HSCT”).

### Claim 18 (depends on 16)

The method of claim 16, wherein the antigen is CMV pp65.

### Claim 19

(canceled)

### Claim 20 (depends on 15)

The method of claim 15, wherein the virus is EBV.

### Claim at position 18

-23. (canceled)

### Claim 24 (depends on 1)

The method of claim 1, wherein the patient has or is suspected of having a cancer, wherein the T cell line recognizes at least one epitope of an antigen of the cancer, and wherein the relative activities are relative measures of known activity against the cancer.

### Claim at position 20

-26. (canceled)

### Claim 27 (depends on 24)

The method of claim 24, wherein the antigen is WT1.

### Claim 28 (depends on 24)

The method of claim 24, wherein the cancer is a lymphoproliferative disorder.

### Claim 29 (depends on 28)

The method of claim 28, wherein the cancer is an EBV-positive post-transplant lymphoproliferative disorder.

### Claim 30 (depends on 29)

The method of claim 29, wherein the antigen is EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, LMP1, or LMP2.

### Claim at position 25

-33. (canceled)

### Claim 34

A method of selecting an allogeneic T cell donor from whom to derive an allogeneic T cell line for therapeutic administration to a human patient having or suspected of having a pathogen or cancer, comprising:
selecting a T cell donor allogeneic to the patient, using a representation that (i) identifies a plurality of HLA alleles and optionally HLA allele combinations, and (ii) discloses indications of relative activities of T cell lines, each recognizing at least one epitope of an antigen of the pathogen or cancer, and restricted to different ones of the HLA alleles or HLA allele combinations in the plurality; wherein in the representation each identified HLA allele or HLA allele combination is associated with the respective indication of relative activity of the T cell line restricted to the HLA allele or HLA allele combination, the relative activities being relative measures of known activity against the pathogen or against the cancer exhibited by the T cell lines; wherein
(A) the T cell donor selected has at least one HLA allele or HLA allele combination in common with the patient or diseased cells in the patient; and
(B) one of the at least one HLA allele or HLA allele combination in common with the patient or the diseased cells in the patient is associated in the representation with an indication of the highest relative activity among the HLA alleles and HLA allele combinations in the representation that are known to be in common with the patient or the diseased cells in the patient and are not otherwise disqualified.

### Claim at position 27

-66. (canceled)

### Claim 67

A method of selecting an allogeneic T cell donor from whom to derive an allogeneic T cell line for therapeutic administration to a human patient having or suspected of having a pathogen or cancer, comprising:
selecting a T cell donor allogeneic to the patient who has in common one or more HLA alleles with the patient or diseased cells in the patient, using a representation that (i) identifies a plurality of HLA alleles, and (ii) discloses indications of relative frequencies of generation of T cell lines, each recognizing at least one epitope of an antigen of the pathogen or the cancer, and restricted to different ones of said HLA alleles in the plurality; wherein in the representation each identified HLA allele is associated with the respective indication of relative frequency of generation of said T cell lines restricted to the HLA allele, wherein:
the T cell donor selected has at least one HLA allele in common with the patient or the diseased cells in the patient that is associated in the representation with an indication of higher frequency of generation than HLA alleles of the donor that are not in common with the patient or the diseased cells in the patient.

### Claim at position 29

-99. (canceled)

### Claim 100 (depends on 1)

A computer system for selecting an allogeneic T cell line for therapeutic administration to a human patient having or suspected of having a pathogen or cancer, comprising:
a central processing unit;
a memory, couple to the central processing unit, the memory storing instructions for performing the steps of the method of claim 1.

### Claim 101 (depends on 1)

A computer readable medium having computer-executable instructions for performing the steps of the method of claim 1.

### Claim 102 (depends on 1)

A method of treating a human patient having or suspected of having a pathogen or cancer, comprising:
(a) selecting an allogeneic T cell line for therapeutic administration to the patient according to the method of claim 1; and
(b) administering a population of T cells derived from the selected allogeneic T cell line to the patient.

### Claim at position 33

-105. (canceled)

### Claim 106 (depends on 34)

A method of obtaining an allogeneic T cell line for therapeutic administration to a human patient having or suspected of having a pathogen or cancer, comprising:
(a) selecting an allogeneic T cell donor according to the method of claim 34; and
(b) deriving an allogeneic T cell line from the selected allogeneic T cell donor, which allogeneic T cell line recognizes at least one epitope of an antigen of the pathogen or cancer.

### Claim 107 (depends on 67)

A method of obtaining an allogeneic T cell line for therapeutic administration to a human patient having or suspected of having a pathogen or cancer, comprising:
(a) selecting an allogeneic T cell donor according to the method of claim 67; and
(b) deriving an allogeneic T cell line from the selected allogeneic T cell donor, which allogeneic T cell line recognizes at least one epitope of an antigen of the pathogen or cancer.
